The estimated Net Worth of Bros. Advisors Lp667, L.P.B... is at least $876 Миллион dollars as of 20 August 2024. Bros B owns over 1 units of Prelude Therapeutics Inc stock worth over $27,584,930 and over the last 7 years Bros sold PRLD stock worth over $848,420,795.
Sign up
Bros B PRLD stock SEC Form 4 insiders trading
Bros has made over 43 trades of the Prelude Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Bros bought 1 units of PRLD stock worth $46 on 20 August 2024.
The largest trade Bros's ever made was buying 5,814,100 units of Prelude Therapeutics Inc stock on 2 August 2018 worth over $627,922,800. On average, Bros trades about 321,496 units every 22 days since 2018. As of 20 August 2024 Bros still owns at least 5,516,986 units of Prelude Therapeutics Inc stock.
You can see the complete history of Bros B stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Prelude Therapeutics Inc
Over the last 5 years, insiders at Prelude Therapeutics Inc have traded over $822,895 worth of Prelude Therapeutics Inc stock and bought 5,875,215 units worth $87,687,261 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., David P Bonita и Advisors Llc Orbi Med Capit.... On average, Prelude Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $608,735. The most recent stock trade was executed by Jane Huang on 4 July 2024, trading 9,375 units of PRLD stock currently worth $46,875.
What does Prelude Therapeutics Inc do?
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware.
What does Prelude Therapeutics Inc's logo look like?
Complete history of Bros B stock trades at Acadia Pharmaceuticals Inc, Aeglea BioTherapeutics Inc, Alexion Pharmaceuticals, BeiGene Ltd, Incyte, Madrigal Pharmaceuticals Inc, Seagen Inc, Zymeworks BC Inc, Kiniksa Pharmaceuticals International Plc, Kodiak Sciences Inc, Bicycle Therapeutics plc, Neoleukin Therapeutics, IGM Biosciences, Kymera Therapeutics и Prelude Therapeutics Inc
Prelude Therapeutics Inc executives and stock owners
Prelude Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Dr. Krishna Vaddi D.V.M., Ph.D.,
Founder, CEO & Director -
Dr. Deborah Morosini,
Exec. VP & Chief of Clinical Affairs -
Naveen Babbar,
Sr. VP of Translation Medicine -
Dr. Madhu Pudipeddi Ph.D.,
Sr. VP of Technical Operations -
Dr. Andrew P. Combs Ph.D.,
Exec. VP & Head of Chemistry -
Michele Porreca,
Chief People Officer -
Dr. Peggy A. Scherle Ph.D.,
Chief Scientific Officer -
Laurent Chardonnet,
Chief Financial Officer -
David P Bonita,
-
Martin Babler,
-
Bros. Advisors Lp667, L.P.B...,
-
Christopher Pierce,
EVP and Chief of Business Oper -
Deborah Morosini,
EVP, Chief of Clinical Affairs -
Advisors Llc Orbi Med Capit...,
-
Paul A Friedman,
-
Krishna Vaddi,
CEO -
David J Mauro,
Chief Medical Officer -
Brian Piper,
Chief Financial Officer -
Laurent Chardonnet,
Chief Financial Officer -
Jane Huang,
President, CMO -
Peggy Scherle,
Chief Scientific Officer -
Bryant David Lim,
CLO, Interim CFO, Corp Sec. -
Bros. Advisors Lp667, L.P.B...,
-
Victor Sandor,
-
Mardi Dier,